SCHEDULE 13G/A: AIGH Capital Management Discloses 6.8% Stake in TELA Bio, Inc. Common Stock

AIGH Capital Management LLC and its affiliates, including Orin Hirschman, have disclosed a 6.8% beneficial ownership stake in TELA Bio, Inc.'s common stock as of December 31, 2024, through an amended Schedule 13G filing.

Summary

• The filing is an Amendment No. 3 to Schedule 13G, reporting beneficial ownership of TELA Bio, Inc. (Issuer: 872381108 CUSIP) common stock.
• The reporting persons are Orin Hirschman, AIGH Capital Management LLC, and AIGH Investment Partners LLC, collectively referred to as the "Reporting Persons."
• As of December 31, 2024, the Reporting Persons collectively beneficially own 2,662,785 shares of TELA Bio, Inc. common stock.
• This ownership represents 6.8% of the total class of TELA Bio, Inc. common stock.
• The Reporting Persons hold sole voting power and sole dispositive power over all 2,662,785 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant passive ownership stake by an institutional investor, which is generally viewed as a neutral to slightly positive signal of confidence in the company, without indicating any immediate operational or financial changes.

Positives

• A significant institutional investor, AIGH Capital Management LLC, holds a substantial stake in TELA Bio, Inc., which can be interpreted as a vote of confidence in the company's long-term prospects.
• The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of influencing control, suggesting a passive, potentially long-term investment approach.

Risks

• The concentration of a significant percentage of shares (6.8%) in the hands of a single institutional investor group means that any future decision by this group to significantly alter its position could impact the stock's liquidity and price.
• The value of the investment is subject to general market conditions and specific performance of TELA Bio, Inc., which could fluctuate.

Future Outlook

NA

Industry Context

This filing reflects a common practice where institutional investors disclose significant passive ownership stakes in publicly traded companies, providing transparency to the market regarding major shareholders. TELA Bio, Inc. operates in the medical technology sector, and such investments indicate investor interest in the company's market position and growth prospects within this industry.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, which can influence investor sentiment and market perception of the stock.
• Company Management: Awareness of a large, passive shareholder who may engage in dialogue but is not seeking control of the company.

Key Dates

Keywords

TELA Bio, AIGH Capital Management, Orin Hirschman, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing, investment, medical technology, healthcare